Ventyx biosciences reports fourth quarter and full year 2023 financial results and highlights recent corporate progress

Ventyx to host virtual investor event on march 11 th to provide clinical updates on our nlrp3 portfolio and from the open-label extension of the vtx002 phase 2 trial in ulcerative colitis

VTYX Ratings Summary

VTYX Quant Ranking